Swedish drug development services provider Inhalation Sciences Sweden has been acquired by a consortium comprising Per Gerde, Fredrik Sjovall, and Rasunda Forvaltning.

"With the aim of further expanding its presence in the US, Quotient Clinical has acquired US-based contract development and manufacturing services provider, QS Pharma."

Per Gerde is the founder of the target company, whereas Fredrik Sjovall is its CEO.

The stake was sold by KDev Investments, an investment firm held jointly by Karolinska Development and Rosetta Capital.

With the aim of further expanding its presence in the US, Quotient Clinical has acquired US-based contract development and manufacturing services provider, QS Pharma.

Based in the UK, Quotient Clinical provides drug development services. The acquisition has been made from Charles River Laboratories International, a US-based pre-clinical and clinical laboratory services provider.